ConductScience.org, home

Paper39200055

Association between Extended Meropenem Regimen and Achievement of Aggressive PK/PD in Patients Receiving Continuous Renal Replacement Therapy for Septic AKI.

Chihara S and 5 others. Antibiotics (Basel), 2024. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Association between Extended Meropenem Regimen and Achievement of Aggressive PK/PD in Patients Receiving Continuous Renal Replacement Therapy for Septic AKI. Papers, record 39200055. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39200055

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Association between Extended Meropenem Regimen and Achievement of Aggressive PK/PD in Patients Receiving Continuous Renal Replacement Therapy for Septic AKI.
PubMed
Journal
Antibiotics (Basel)
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.44, provisional
iCite
Revised in PubMed
2024-09-01
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chihara SShinya
2Ishigo TTomoyukihttps://orcid.org/0000-0002-2689-5338
3Kazuma SSatoshi
4Matsumoto KKana
5Morita KKunihiko
6Masuda YYoshiki

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112660337Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome.J Am Soc Nephrol2003https://conductscience.org/library/papers/12660337PubMed
229091190Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships.J Antimicrob Chemother2017https://conductscience.org/library/papers/29091190PubMed
316211527Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis.Int J Artif Organs2005https://conductscience.org/library/papers/16211527PubMed
436005753Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/36005753PubMed
521914174Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.Crit Care2011https://conductscience.org/library/papers/21914174PubMed
612940901Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis.Artif Organs2003https://conductscience.org/library/papers/12940901PubMed
720479205Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.Antimicrob Agents Chemother2010https://conductscience.org/library/papers/20479205PubMed
824026297De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock.Intensive Care Med2014https://conductscience.org/library/papers/24026297PubMed
938627763
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis.
Crit Care2024https://conductscience.org/library/papers/38627763PubMed
1024886826β-lactam antibiotic concentrations during continuous renal replacement therapy.Crit Care2014https://conductscience.org/library/papers/24886826PubMed
1125636084The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.Crit Care2014https://conductscience.org/library/papers/25636084PubMed
1229102324Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.Lancet Infect Dis2018https://conductscience.org/library/papers/29102324PubMed
1326903338The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).JAMA2016https://conductscience.org/library/papers/26903338PubMed
1434999376Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).J Crit Care2022https://conductscience.org/library/papers/34999376PubMed
1537125925Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.Antimicrob Agents Chemother2023https://conductscience.org/library/papers/37125925PubMed
1630304491Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.J Antimicrob Chemother2018https://conductscience.org/library/papers/30304491PubMed
1721884474In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration.Ther Apher Dial2011https://conductscience.org/library/papers/21884474PubMed
1818027987Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.Clin Pharmacokinet2007https://conductscience.org/library/papers/18027987PubMed
1912970037Vital organ blood flow during hyperdynamic sepsis.Chest2003https://conductscience.org/library/papers/12970037PubMed
2032301057Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.Pharmacol Rep2020https://conductscience.org/library/papers/32301057PubMed

See all 36 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn Papers
42711757
Prediction of the clinical outcomes of imipenem and meropenem in patients with treatment-associated AKI and death via machine learning models combined with pharmacokinetic parameters: A retrospective cohort study.
Sci Prog2026https://conductscience.org/library/papers/42711757

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39200055

GET https://conductscience.org/api/papers/v1/39200055/references?page=2